Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial

By Kurosumi Masafumi   Takatsuka Yuichi   Watanabe Toru   Imoto Shigeru   Inaji Hideo   Tsuda Hitoshi   Akiyama Futoshi   Sakamoto Goi   Ikeda Tadashi   Noguchi Shinzaburo  

Journal of Cancer Research and Clinical Oncology, Vol. 134, Iss. 6, 2008-06 ,pp. : 715-722

Springer Publishing Company

Access to resources Recommend Favorite

Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study

By Aihara Tomohiko  

Breast Cancer Research and Treatment, Vol. 121, Iss. 2, 2010-06 ,pp. : 379-387

Springer Publishing Company

Access to resources Recommend Favorite

Effects of tamoxifen on bone mineral density and metabolism in postmenopausal women with early-stage breast cancer

By Zidan Jamal   Keidar Zohar   Basher Walid   Israel Ora  

Medical Oncology, Vol. 21, Iss. 2, 2004-06 ,pp. : 117-121

Humana Press, Inc

Access to resources Recommend Favorite

Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole

By Skedgel C.   Rayson D.   Dewar R.   Younis T.  

Breast Cancer Research and Treatment, Vol. 101, Iss. 3, 2007-03 ,pp. : 325-333

Springer Publishing Company

Access to resources Recommend Favorite

Anastrozole (Arimidex(TM)) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results

By Nabholtz J.M.   Bonneterre J.   Buzdar A.   Robertson J.F.R.   Thurlimann B.   for the Arimidex Writing Committee on behalf of the Investigators  

European Journal of Cancer, Vol. 39, Iss. 12, 2003-08 ,pp. : 1684-1689

Elsevier

Access to resources Recommend Favorite